Optimal Prescriptions of Continuous Renal Replacement Therapy in Neonates with Hyperammonemia

Area of Science:

• Neonatal Medicine
• Pediatric Nephrology
• Metabolic Disorders

Background:

• Hyperammonemia is a critical condition in neonates, often stemming from inborn errors of metabolism (IEM).
• Elevated ammonia levels can lead to severe neurological damage and mortality in newborns.
• Effective management strategies for neonatal hyperammonemia are crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate patient outcomes in neonates treated with continuous renal replacement therapy (CRRT) for hyperammonemia.
• To determine optimal CRRT prescriptions for reducing serum ammonia levels.
• To identify prognostic factors associated with outcomes in neonates with hyperammonemia.

Main Methods:

• Retrospective analysis of medical records from 12 Korean neonates with IEM and hyperammonemia.
• All neonates underwent continuous venovenous hemodiafiltration (CVVHDF).
• Key parameters analyzed included ultrafiltration rate (UFR), ammonia levels, time to ammonia reduction, and neurological sequelae.

Main Results:

• CRRT effectively reduced serum ammonia levels, with a median 50% reduction achieved in 12.8 hours.
• The median ultrafiltration rate at CRRT initiation was 2,288.4 mL/h/1.73 m2.
• Hospital survival rate was 83.3%, with neurological sequelae linked to higher peak and initial ammonia levels.

Conclusions:

• CRRT is a viable therapeutic option for managing hyperammonemia in neonates with IEM.
• Higher UFRs, exceeding 4,000 mL/h/1.73 m2, may be necessary for neonates presenting with very high initial ammonia levels.
• Early and aggressive management with CRRT, potentially at higher UFRs, can improve survival and reduce neurological complications.